Details for Patent: RE49582

Which drugs does patent RE49582 protect, and when does it expire?

Patent RE49582 protects AQVESME and PYRUKYND and is included in one NDA.

This patent has sixty-one patent family members in thirty-seven countries.

Summary for Patent: RE49582

Title:	Therapeutic compounds and compositions
Abstract:	Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
Inventor(s):	Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
Assignee:	Schroedinger LLC , Agios Pharmaceuticals Inc
Application Number:	US17/131,562
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent RE49582

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196-004	Dec 23, 2025		RX	Yes	Yes			Y	Y
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No			Y	Y
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-002	Feb 17, 2022		RX	Yes	No			Y	Y
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes			Y	Y

International Family Members for US Patent RE49582

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2448582		301230	Netherlands
European Patent Office	2448582		CA 2023 00014	Denmark
European Patent Office	2448582		2023C/517	Belgium
European Patent Office	2448582		LUC00306	Luxembourg